New Study for Catalyst CSR Total Shoulder System Demonstrates Good Results In Adult Arthroplasty Pat

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced a new study recently published in the Journal of Shoulder and Elbow Surgery that shows positive data around the use of the Catalyst CSR™ Total Shoulder System in adult arthroplasty patients of all ages, rather than just younger patients. The retrospective case series examines the initial cohort of patients that received an anatomic total shoulder arthroplasty (TSA) using the Catalyst CSR system from August 2016 to August 2017. Patients were evaluated at multiple time points postoperatively with a minimum of two-year follow-up.

The selection criteria of patients were broad and included all patients with “glenohumeral joint arthritis with an intact rotator cuff, regardless of patient age.” No cases in this continuous series of patients were converted to a stemmed TSA device intraoperatively due to bone quality. This has not been the case in previous studies for stemless implants,1 and may be attributed to the unique, patented design of the Catalyst CSR humeral implant. This is also the first study to report clinical outcomes using an ellipsoid-shaped humeral head implant, which better resembles the native humeral shape and has been shown to perform superiorly in biomechanical studies.2, 3 Catalyst OrthoScience is the first orthopedic company to offer ellipsoid implants to patients.

Catalyst OrthoScience is a Fund III portfolio company. Read more about the results of the study here